XML 53 R37.htm IDEA: XBRL DOCUMENT

Segment, Geographical and Other Revenue Information (Tables)

12 Months Ended

Dec. 31, 2021

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):


	Year Ended December 31, 2021						Year Ended December 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	70,657	$	—	$	70,657	$	30,220	$	—	$	30,220
Research and development revenue	19,858		14,239		34,097		17,886		20,950		38,836
Total revenues	90,515		14,239		104,754		48,106		20,950		69,056
Costs and operating expenses:
Cost of product revenue	22,209		—		22,209		13,742		—		13,742
Research and development (1)	23,140		30,219		53,359		20,923		21,705		42,628
Selling, general and administrative(1)	12,105		2,755		14,860		9,597		2,355		11,952
Total segment costs and operating expenses	57,454		32,974		90,428		44,262		24,060		68,322
Income (loss) from operations	$	33,061	$	(18,735)	14,326		$	3,844	$	(3,110)	734
Corporate costs (2)					(32,201)						(22,306)
Depreciation and amortization					(3,215)						(2,099)
Loss before income taxes					$	(21,090)					$	(23,671)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.

(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income (expense), net.


	Year Ended December 31, 2020						Year Ended December 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	30,220	$	—	$	30,220	$	29,465	$	—	$	29,465
Research and development revenue	17,886		20,950		38,836		28,691		10,302		38,993
Total revenues	48,106		20,950		69,056		58,156		10,302		68,458
Costs and operating expenses:
Cost of product revenue	13,742		—		13,742		15,632		—		15,632
Research and development (1)	20,923		21,705		42,628		19,380		13,278		32,658
Selling, general and administrative(1)	9,597		2,355		11,952		8,462		2,222		10,684
Total segment costs and operating expenses	44,262		24,060		68,322		43,474		15,500		58,974
Income (loss) from operations	$	3,844	$	(3,110)	734		$	14,682	$	(5,198)	9,484
Corporate costs (2)					(22,306)						(19,624)
Depreciation and amortization					(2,099)						(1,778)
Loss before income taxes					$	(23,671)					$	(11,918)

(1) For the years ended December 31, 2020 and 2019, research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.

(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income (expense), net.

The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):


	Year Ended December 31,
	2021		2020		2019
Performance Enzymes	$	4,514	$	2,970	$	2,303
Novel Biotherapeutics	1,100		768		695
Corporate cost	5,979		3,990		3,945
Total	$	11,593	$	7,728	$	6,943

Schedule of Customers That Contributed 10% or More of Total Accounts Receivable

Customers that each accounted for 10% or more of our total revenues were as follows:


	Percentage of Total Revenues For the Year Ended December 31,
	2021		2020		2019
Customer A	33	%	*		*
Customer B	11	%	26	%	28	%
Customer C	*		19	%	*
Customer D	*		11	%	15	%
Customer E	*		*		23	%

* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:


	As of December 31,
	2021		2020
Customer A	62	%	*
Customer B	*		32	%
Customer D	*		13	%
Customer E	*		25	%

* Percentage was less than 10%

Schedule of Revenues by Geographical Area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Year Ended December 31,
	2021		2020		2019
Revenues
Americas	$	23,481	$	24,352	$	13,039
EMEA	20,187		19,257		37,133
APAC	61,086		25,447		18,286
Total revenues	$	104,754	$	69,056	$	68,458

Schedule of Long-lived Assets by Geographical Area

Identifiable long-lived assets by location were as follows (in thousands):


	December 31,
	2021		2020
United States	$	65,457	$	31,176

Schedule of Intangible Assets and Goodwill

Identifiable goodwill was as follows (in thousands):`


	December 31, 2021						December 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241	$	2,463	$	778	$	3,241